Preclinical News and Research

RSS

Sequella receives FDA fast track status for pulmonary tuberculosis drug

Sequella, Inc. has announced it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for SQ109, the company's proprietary lead drug candidate for treatment of pulmonary tuberculosis (TB).

22 Jan 2007

Novavax's pandemic flu vaccines show promise

Novavax, Inc.'s novel virus-like particle (VLP) vaccines have been shown to be effective in generating protection against pandemic influenza as well as cross protection against different strains of the virus in pre-clinical studies, according to data presented at the Phacilitate Vaccine Forum.

22 Jan 2007

Amphora sells oncology target to Genentech

Amphora Discovery Corporation, a small molecule drug discovery company, announced today that it has entered into an agreement with Genentech, Inc. pursuant to which Genentech will purchase Amphora's entire program for an unnamed oncology target with the potential to treat multiple oncology indications.

9 Jan 2007

NanoMed Pharmaceuticals issued new U.S. nanoparticle patent

NanoMed Pharmaceuticals has announced that founders Russell J. Mumper, Ph.D. and Michael Jay, Ph.D. have been issued U.S. Patent 7,153,525 entitled "Microemulsions As Precursors To Solid Nanoparticles."

3 Jan 2007

New treatment for lower back pain using patient's own stem cells

A University of Manchester researcher has developed a treatment for lower back pain using the patient's own stem cells, which could replace the use of strong painkillers or surgery that can cause debilitation, neither of which addresses the underlying cause.

From The University of Manchester 2 Dec 2006

Cytogen issued new patent covering oral drug delivery agents

Cytogen Corporation has announced that it has been issued United States patent number 7,135,457 covering its oral drug delivery agents - random peptide compositions that bind to gastro-intestinal tract (GIT) transport receptors.

28 Nov 2006

FDA approves silicone gel-filled breast implants

After rigorous scientific review, the U.S. Food and Drug Administration (FDA) has approved the marketing of silicone gel-filled breast implants made by two companies for breast reconstruction in women of all ages and breast augmentation in women ages 22 and older.

19 Nov 2006

Bionomics delivers on milestones for cancer, anxiety and multiple sclerosis programs

Australian drug discovery company Bionomics Limited today updated shareholders at its Annual General Meeting on the recent progress of its anti-cancer drug BNC105 and drug discovery programs in anxiety and Multiple Sclerosis.

8 Nov 2006

Turmeric for prevention of rheumatoid arthritis and osteoporosis

An ancient spice, long used in traditional Asian medicine, may hold promise for the prevention of both rheumatoid arthritis and osteoporosis, according to a recently completed study at The University of Arizona College of Medicine.

30 Oct 2006

New study emphasizes the importance of metabolomics to the advent of personalized medicine

International experts have collaborated on a comprehensive collection of reviews focusing on the emerging interface between metabolomics and pharmacogenomics.

24 Oct 2006

Topical treatment for psoriasis, eliminates need for injections

Apollo Life Sciences, a Sydney-based biotechnology company, has announced that its topical psoriasis treatment has outperformed current market-leading drugs in preclinical studies.

17 Oct 2006

California agency releases 10-year plan for spending $3B on embryonic stem cell research

The California Institute for Regenerative Medicine -- which is in charge of implementing the 10-year, $2.95 billion state human embryonic stem cell research program approved under Proposition 71 -- on Wednesday released a draft spending plan that "sets a strikingly modest tone" for outcomes of the research.

5 Oct 2006

Bristol-Myers Squibb and Medivira announce collaboration to commercialize HIV treatment

Bristol-Myers Squibb and Medivir AB have announced a worldwide collaboration to develop and commercialize MIV-170, a preclinical non-nucleoside reverse transcriptase inhibitor, or NNRTI, intended for the treatment of HIV-1 infection in adults as part of an antiretroviral drug regimen.

13 Sep 2006

First step to developing effective therapy against Venezuelan Equine Encephalitis virus

Biomedical researchers at the University of Texas Medical Branch at Galveston (UTMB) have taken an important early step toward developing effective drug therapies against Venezuelan Equine Encephalitis (VEE) virus, a potential bioterrorist weapon.

12 Sep 2006

Weight loss may be a preclinical indicator of Alzheimer's disease

The slow, steady weight loss associated with aging may speed up prior to the onset of Alzheimer's disease and related dementias, according to an article in the September issue of Archives of Neurology.

12 Sep 2006

Reactive oxygen species in cancer cells

A biochemical alteration that has long been viewed as an adverse aspect of tumor biology may turn out to be a deadly double-edged sword for the cancer cells themselves.

12 Sep 2006

U.S. Army to trial of Glypromate to reduce brain injury from cardiac arrest

Neuren Pharmaceuticals today announced that physicians from Madigan Army Medical Center (Madigan) in Tacoma, Washington, will conduct an investigator- initiated Phase 2 trial to determine the safety and efficacy of Glypromate in reducing brain injury caused by out of hospital cardiac arrest.

4 Sep 2006

Neuren presents phase 2 clinical trial strategy for NNZ-2566

Neuren Pharmaceuticals has announced that Mr Larry Glass, Executive Vice President and head of Neuren’s US operations, has been invited by the US Army to present Neuren’s clinical trial strategy for NNZ-2566 at the Advanced Technology Applications for Combat Casualty Care (ATACCC) conference.

14 Aug 2006

Oragenics issued new patent for novel antibiotic peptide

Oragenics has announced that the US Patent office has issued a fourth patent (No. 7,067,125), that further describes the composition and uses of the company's exclusively licensed novel antibiotic peptide, MU1140.

8 Aug 2006

Link between psychological stress and ovarian tumor growth

When mice with ovarian cancer are stressed, their tumors grow and spread more quickly, but that effect can be blocked using a medication commonly prescribed for heart disease.

24 Jul 2006